Introduction
Carcinogenicity testing, as described in OECD Test Guideline 453, is designed to detect the potential of a chemical substance to cause cancer following prolonged exposure. This guideline outlines a combined chronic toxicity and carcinogenicity study conducted in rodents over a period of 18 to 24 months. These long-term studies are essential for identifying tumorigenic risks and are critical components of safety evaluations for pharmaceuticals, industrial chemicals, environmental agents, and consumer products.
OECD 453 plays a pivotal role in determining whether a substance possesses the capacity to induce neoplastic lesions and in establishing dose-response relationships for regulatory classification and risk assessment.
Purpose and Regulatory Role
The primary objective of OECD 453 studies is to detect both non-neoplastic and neoplastic effects resulting from repeated exposure to a test substance over the majority of the animal’s life. The data generated are used by regulatory agencies worldwide, including the FDA, EMA, EPA, and IARC, to classify substances according to carcinogenic risk categories and to inform decisions about labeling, exposure limits, and product approvals.
In drug development, carcinogenicity studies are often required for compounds intended for long-term human use, especially those with structural alerts or mechanistic evidence suggesting oncogenic potential. For environmental and industrial chemicals, these studies form the basis of hazard identification and quantitative cancer risk modeling.
Study Design and Methodology
A typical OECD 453 study is conducted in rats, with at least 50 animals per sex per dose group. The study includes at least three dose levels in addition to a concurrent vehicle control. The test substance is administered daily via oral, dermal, or inhalation routes, depending on intended human exposure, over a duration of up to 104 weeks.
Throughout the study, animals are monitored for survival, body weight, clinical signs, food and water intake, and the development of palpable masses. Interim evaluations may include clinical pathology and toxicokinetics. At study termination—or when animals reach humane endpoints—a complete necropsy is performed, followed by histopathological examination of a broad range of tissues and organs, with special attention to any masses or lesions.
The dual objectives of the OECD 453 study—chronic toxicity and carcinogenicity—allow for a comprehensive assessment of both early toxic effects and long-latency tumorigenic processes.
Tumor Assessment and Interpretation
Histopathological evaluation is conducted on all organs, with special scrutiny of known tumor target sites such as the liver, lungs, mammary glands, kidneys, gastrointestinal tract, and hematopoietic system. Tumor classification includes benign versus malignant differentiation, tissue of origin, invasiveness, and metastatic potential.
Statistical analysis is used to determine treatment-related trends in tumor incidence and progression. Dose-response relationships are assessed using survival-adjusted methods, and findings are interpreted in the context of historical control data, biological plausibility, and mechanistic understanding.
If mechanistic data are available—such as genotoxicity, hormonal modulation, or receptor-mediated effects—they are used to contextualize the carcinogenic response and evaluate human relevance.
Applications in Risk Assessment and Product Development
The results of OECD 453 studies support carcinogen classification schemes under global frameworks such as the GHS and CLP, as well as the regulatory evaluation of lifetime exposure risk for humans. For drug development, these studies are often required before approval of medications intended for chronic use. The data also inform clinical safety monitoring strategies and guide long-term patient management.
For industrial chemicals and environmental agents, these studies are critical for establishing maximum residue levels, workplace exposure limits, and public health guidelines.
Integration with Other Toxicological Endpoints
Carcinogenicity studies are often performed as part of a broader toxicological assessment program. Data from genotoxicity, reproductive toxicity, subchronic toxicity (OECD 408), and chronic toxicity (OECD 452) help inform interpretation of tumor findings. Inclusion of satellite groups or molecular endpoints can support mechanistic hypotheses and increase the interpretability of complex responses.
Altogen Labs Long-Term Carcinogenicity Services
Altogen Labs offers GLP-compliant carcinogenicity testing services aligned with OECD 453 guidelines. Our studies are conducted using well-characterized rodent models with comprehensive histopathological and statistical support. Study designs are customized to reflect the intended human exposure route and therapeutic context of each compound.
Our experienced toxicologists manage all aspects of study execution, including dose formulation, long-term animal care, necropsy, tissue processing, and pathology review. We support IND submissions, ICH-compliant drug development, and regulatory filings for chemical safety and consumer products. Altogen Labs provides end-to-end services from study initiation through submission-ready reporting, ensuring scientific rigor and regulatory acceptance.